
Claims

1. An antibody-drug conjugate of the formula (I)



(I)

in which

X_1	represents CH,
X_2	represents C and
X_3	represents N;
R^1	represents hydrogen or methyl,
R^2	represents methyl, $-CH_2-CH(CH_3)_2$, $-CH_2-C(=O)OH$ or isopropyl,
R^3	represents methyl, $-CH_2-CH(CH_3)_2$ or $-CH_2-C(=O)-NH_2$,

M represents the group

#-C(=O)-CH(CH_3)-NH-C(=O)-CH_2-W,

#-C(=O)-CH_2-NH-C(=O)-CH_2-CH(##)-COOH,

#-C(=O)-CH_2-NH-C(=O)-CH(##)-CH_2-COOH,

#-C(=O)-CH_2-W,

#-C(=O)-CH(CH_3)-NH-C(=O)-$(CH_2)_3$-C(=O)-###,


#-C(=O)- $(CH_2)_3$-C(=O)-###,

#-C(=O)-CH(CH_3)-NH-C(=O)-$(CH_2)_5$-W,

#-C(=O)-CH(CH_3)-NH-C(=O)-(CH_2)-## or

#-C(=O)-CH(CH_3)-NH-C(=O)-$(CH_2$-CH_2-$O)_4$-$(CH_2)_2$-NH-C(=O)-CH_2-##,

W represents the group



n represents a number from 1 to 50,

AK represents an antibody or an antigen-binding antibody fragment,

represents the bond to the compound,

represents the bond to a sulfur atom of a cysteine side-chain of the antibody or an antigen-binding antibody fragment,

represents the bond to a nitrogen atom of a lysine side-chain of the antibody or an antigen-binding antibody fragment,

and their salts, solvates and salts of these solvates.

2. The antibody-drug conjugate of claim 1, wherein R^1 represents methyl.

3. The antibody-drug conjugate according to Claims 1 or 2, wherein

R^1	represents methyl,
R^2	represents methyl or isopropyl,
R^3	represents methyl or $–CH_2$-C(=O)-NH_2,
M	represents the group
	#-C(=O)-CH(CH_3)-NH-C(=O)-(CH_2)$_3$-C(=O)-###,
n	represents a number from 1 to 50,
AK	represents the antibody or an antigen-binding antibody fragment,
#	represents the bond to the compound,
###	represents the bond to a nitrogen atom of a lysine side-chain of the antibody or an antigen-binding antibody fragment,

and their salts, solvates and salts of these solvates.

4. The antibody-drug conjugate according to any one of Claims 1 to 3, wherein

R^1	represents methyl,
R^2	represents methyl,
R^3	represents $–CH_2$-C(=O)-NH_2,
M	represents the group
	#-C(=O)-CH(CH_3)-NH-C(=O)-(CH_2)$_3$-C(=O)-###,
n	represents a number from 1 to 50,
AK	represents an antibody or an antigen-binding antibody fragment,
#	represents the bond to the compound,

represents the bond to a nitrogen atom of a lysine side-chain of the antibody or an antigen-binding antibody fragment,

and their salts, solvates and salts of these solvates.

5. The antibody-drug conjugate according to any one of Claims 1 to 4, wherein

R^1 represents methyl,

R^2 represents methyl,

R^3 represents $–CH_2-C(=O)-NH_2$,

M represents the group

#-C(=O)-CH(CH_3)-NH-C(=O)-$(CH_2)_3$-C(=O)-###,

n represents a number from 1 to 20 and

AK represents an anti-B7H3 antibody, an anti-TWEAKR antibody, an anti-Her2 antibody or an anti-EGFR antibody or represents an antigen-binding antibody fragment of these,

represents the bond to the compound,

represents the bond to a nitrogen atom of a lysine side-chain of the antibody (AK) or of the antigen-binding antibody fragment thereof,

and their salts, solvates and salts of these solvates.

6. The antibody-drug conjugate according to any one of Claims 1 to 5, wherein

R^1 represents methyl,

R^2 represents methyl,

R^3 represents $–CH_2-C(=O)-NH_2$,

M represents the group

#-C(=O)-CH(CH_3)-NH-C(=O)-$(CH_2)_3$-C(=O)-###,

n represents a number from 1 to 20 and


AK represents an anti-B7H3 antibody TPP-8382, an anti-TWEAKR antibody TPP-7006 or TPP-7007, an anti-Her2 antibody TPP-1015 or an anti-EGFR antibody TPP- 981 or an antigen-binding antibody fragment thereof,

represents the bond to the compound,


represents the bond to a nitrogen atom of a lysine side-chain of the antibody or of the antigen-binding antibody fragment thereof,

and their salts, solvates and salts of these solvates.


7. The antibody-drug conjugate according to Claim 1, having the structures




,




,




,




.



,



and



wherein


AK1 represents AK attached via a sulfur atom of a cysteine side-chain,

AK2 represents AK attached via a nitrogen atom of a lysine side-chain and

n represents 1 to 50,

and their salts, solvates and salts of these solvates.

8. The antibody-drug conjugate according to any one of Claims 1-7, having the structure



wherein

AK2 represents an antibody which is attached via a nitrogen atom of a lysine side-chain, and

n represents 1 to 20,

and their salts, solvates and salts of these solvates.

9. The antibody-drug conjugate according to any one of Claims 1 to 8, wherein n represents 1 to 8, and their salts, solvates and salts of these solvates.

10. The antibody-drug conjugate according to any one of Claims 1 to 8, wherein n represents 4 to 8, and their salts, solvates and salts of these solvates.

11. The antibody-drug conjugate according to any one of Claims 1 to 10, wherein AK, AK1, or AK2 represents TPP-8382, or an antigen-binding fragment thereof.

12. The antibody-drug conjugate according to any one of Claims 1 to 10, wherein AK, AK1 or AK2 represents an anti-B7H3 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 52, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 53 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 54, and a variable region of

the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 56, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 57 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 58, or AK, AK1, or AK2 represents an antigen-binding fragment of these antibodies.

13. The antibody-drug conjugate according to any one of Claims 1 to 10 wherein AK, AK1, or AK2 represents an anti-B7H3 antibody comprising a variable region of the heavy chain (VH) as shown in SEQ ID NO: 51 and a variable region of the light chain (VL) as shown in SEQ ID NO: 55, or AK, AK1, or AK2 represents an antigen-binding fragment of these antibodies.

14. The antibody-drug conjugate according to any one of Claims 1 to 10, where AK, AK1, or AK2 represents an anti-B7H3 antibody comprising a region of the heavy chain as shown in SEQ ID NO: 59 and a region of the light chain as shown in SEQ ID NO: 60, or AK, AK1, or AK2 represents an antigen-binding fragment of these antibodies.

15. The antibody-drug conjugate according to any one of Claims 1 to 14, wherein the antibody or the antigen-binding antibody fragment binds to an extracellular target molecule.

16. The antibody-drug conjugates according to any one of Claims 1 to 15, wherein the antibody or the antigen-binding antibody fragment binds to an extracellular cancer target molecule.

17. The antibody-drug conjugates according to Claim 15, wherein the antibody or the antigen-binding antibody fragment, after binding to its extracellular target molecule on the target cell, is internalized by the target cell through the binding.

18. A pharmaceutical composition comprising at least one antibody-drug conjugate according to any one of claims 1-17 in combination with an inert, non-toxic, pharmaceutically suitable auxiliary.

19. The antibody-drug conjugates according to any one of claims 1-17 for use in a method for the treatment and/or prophylaxis of diseases.

20. The antibody-drug conjugates according to any one of claims 1-17 for use in a method for the treatment of hyperproliferative and/or angiogenic disorders.

21. The antibody-drug conjugates according to any one of claims 1-17 for use in a method for the treatment of cancer and tumours.

22. The antibody-drug conjugates according to any one of claims 1-17 for use in a method for the treatment of cancer and tumours in combination with one or more therapeutic approaches for cancer immunotherapy or with one or more active compounds directed against a molecular target of cancer immunotherapy.